drugset / Trial / NCT00591422

Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

NCT00591422

Phase 1 Unknown 23 enrolled Alaunos Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

The study of Dariniparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

Timeline

Start
2007-08
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Darinaparsin Small molecule 100 mg Oral
Subject Darinaparsin Small molecule 1000 mg Oral